Octagon to address process problems in clinical R&D
now claiming to be the first company to address the process problem
in clinical R&D by offering "an end-to-end solution that
crosses traditional functional boundaries."
The process-solutions provider has bought California-based Ninaza, whose EDC technology will now be integrated across Octagon's Phase I-IV clinical trial offerings. According to Octagon, this will provide the firm with full "collection-to-submission" electronic capabilities and will allow for process efficiency throughout the clinical data lifecycle by automating the collection of electronic clinical data in concert with process facilitation and visibility. "The acquisition of a proven electronic data capture technology completes a critical aspect of our vision. We are working hard to provide transparent, cross-functional technologies and processes that facilitate the efficient management of electronic clinical data across the enterprise," said Jim Walker, chairman and CEO of Octagon. "Most vendors are [just] talking about end-to-end solutions within the functionally isolated market that they address. We are going beyond the point solution mentality which is where true cost and time savings can be brought to bear." Octagon is the first company to address the process problem in clinical research and development by offering an end-to-end solution that crosses traditional functional boundaries.
